Mosaic Valuation

Is 0K3B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0K3B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0K3B ($26.15) is trading below our estimate of fair value ($44.38)

Significantly Below Fair Value: 0K3B is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0K3B?

Key metric: As 0K3B is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0K3B. This is calculated by dividing 0K3B's market cap by their current earnings.
What is 0K3B's PE Ratio?
PE Ratio22.3x
EarningsUS$371.20m
Market CapUS$8.27b

Price to Earnings Ratio vs Peers

How does 0K3B's PE Ratio compare to its peers?

The above table shows the PE ratio for 0K3B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average23.7x
CRDA Croda International
30.4x15.1%UK£4.9b
JMAT Johnson Matthey
23.8x28.4%UK£2.6b
MNDI Mondi
16.2x15.8%UK£5.3b
FRES Fresnillo
24.3x33.0%UK£4.8b
0K3B Mosaic
22.3x26.9%US$8.3b

Price-To-Earnings vs Peers: 0K3B is good value based on its Price-To-Earnings Ratio (22.3x) compared to the peer average (23.7x).


Price to Earnings Ratio vs Industry

How does 0K3B's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0K3B 22.3xIndustry Avg. 17.1xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0K3B is expensive based on its Price-To-Earnings Ratio (22.3x) compared to the European Chemicals industry average (16.9x).


Price to Earnings Ratio vs Fair Ratio

What is 0K3B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0K3B PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.3x
Fair PE Ratio24.5x

Price-To-Earnings vs Fair Ratio: 0K3B is good value based on its Price-To-Earnings Ratio (22.3x) compared to the estimated Fair Price-To-Earnings Ratio (24.5x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0K3B forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$26.15
US$32.74
+25.2%
17.4%US$44.00US$25.00n/a19
Nov ’25US$26.91
US$33.14
+23.2%
17.4%US$45.00US$26.00n/a19
Oct ’25US$27.18
US$34.19
+25.8%
18.2%US$50.00US$26.00n/a20
Sep ’25US$28.45
US$34.29
+20.5%
17.8%US$50.00US$26.00n/a20
Aug ’25US$28.78
US$35.14
+22.1%
16.4%US$50.00US$27.00n/a20
Jul ’25US$28.12
US$35.79
+27.3%
14.8%US$50.00US$27.00n/a20
Jun ’25US$30.57
US$35.76
+17.0%
14.5%US$50.00US$27.00n/a20
May ’25US$29.85
US$37.39
+25.3%
11.9%US$50.00US$31.00n/a20
Apr ’25US$32.37
US$37.76
+16.7%
13.6%US$50.00US$31.00n/a22
Mar ’25US$31.75
US$38.41
+21.0%
13.9%US$50.00US$31.00n/a22
Feb ’25US$30.95
US$39.11
+26.4%
13.4%US$50.00US$31.00n/a21
Jan ’25US$35.56
US$40.11
+12.8%
14.6%US$54.00US$31.00n/a21
Dec ’24US$36.76
US$40.53
+10.3%
13.9%US$54.00US$31.00n/a21
Nov ’24US$32.13
US$42.34
+31.8%
12.7%US$54.00US$32.00US$26.9121
Oct ’24US$35.89
US$43.24
+20.5%
12.6%US$55.00US$32.00US$27.1821
Sep ’24US$39.97
US$42.91
+7.4%
12.9%US$55.00US$32.00US$28.4522
Aug ’24US$40.20
US$42.12
+4.8%
13.6%US$55.00US$32.00US$28.7822
Jul ’24US$35.34
US$43.80
+24.0%
14.4%US$62.00US$35.00US$28.1222
Jun ’24US$32.17
US$44.62
+38.7%
15.2%US$62.00US$35.00US$30.5722
May ’24US$42.40
US$52.00
+22.6%
17.3%US$70.00US$38.00US$29.8522
Apr ’24US$45.58
US$54.69
+20.0%
17.0%US$78.00US$40.00US$32.3722
Mar ’24US$54.29
US$54.63
+0.6%
16.6%US$78.00US$40.00US$31.7523
Feb ’24US$48.79
US$56.44
+15.7%
18.5%US$80.00US$39.00US$30.9523
Jan ’24US$43.60
US$61.33
+40.7%
15.5%US$92.00US$44.00US$35.5622
Dec ’23US$49.46
US$61.85
+25.0%
15.3%US$92.00US$44.00US$36.7621
Nov ’23US$54.31
US$64.28
+18.4%
16.1%US$93.00US$44.00US$32.1321

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies